Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer

Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Neoplasms Digestive System Diseases Digestive System Neoplasms Liver Diseases Neoplasms Neoplasms by Site

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Gasthuisberg

Leuven, Vlaams-Brabant, 3000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Unresectable metastatic liver cancer
No invasion of major biliary structures
No invasion of major vascular structures
ASA score < 4
WHO score 0-1
Pre-operative chemotherapy is allowed

Exclusion criteria

Resectable liver metastases
Life expectancy less than 3 months
Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials
Coagulopathy with platelet count less than 50000
Active infectious disease
Age below 18 years
Pregnancy of breastfeeding

Treatment and study plan

microwave ablation

Device

Liver tumors are destructed/ablated using single-probe microwave energy device

Other names: MW ablation antenna (VT2237) and a 915 MHz Valleylab MW generator (VTSYS3; Covidien, Europe NV)

Radiofrequency Ablation

Device

Liver tumors are destructed/ablated using radiofrequency energy device

Primary outcomes

Variability of ablation diameters

Time frame: within the first 7 days and 3 months after surgery

Sponsors and collaborators

Lead sponsor

University Hospital, Gasthuisberg

Other

Registry information

Official study title

Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible

Acronym: LiverMWA1

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Jun 17, 2009
Registry last updated: Nov 16, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed